Overview

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Adalimumab
Antirheumatic Agents
Ixekizumab